Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Progress in CRC Precision Medicine

February 26th 2018

Emerging Immunotherapy Combinations in MSS CRC

February 26th 2018

Managing Toxicities With Immunotherapy in CRC

February 26th 2018

Dosing and Side Effect Management in Metastatic CRC

February 26th 2018

Third-Line Treatment in Refractory CRC

February 26th 2018

Immunotherapy Options in Refractory CRC

February 26th 2018

Supportive Care in Metastatic CRC

February 26th 2018

Maintenance and Second-Line Decisions in CRC

February 26th 2018

Frontline Antibody Selection in Metastatic CRC

February 26th 2018

Left- Versus Right-Sided Tumors in CRC

February 26th 2018

Importance of HER2 Expression in CRC

February 26th 2018

Role of Molecular Testing in CRC Management

February 26th 2018

Early-Onset CRC: What Do We Know?

February 26th 2018

Treating Liver or Peritoneal Metastases in CRC

February 26th 2018

Managing Patients After Adjuvant Therapy

February 26th 2018

Duration of Adjuvant Therapy: CRC Subsets

February 26th 2018

Deciding on Adjuvant Therapy in CRC

February 26th 2018

Dr. Bekaii-Saab on the Impact of Regorafenib in CRC

February 23rd 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the impact of regorafenib (Stivarga) on the treatment of patients with colorectal cancer (CRC).

Dr. Overman on Remaining Questions With Immunotherapy in CRC

February 20th 2018

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the remaining questions with immunotherapy in colorectal cancer.

Dr. Andre Discusses the Future of Immunotherapy in mCRC

February 20th 2018

Thierry Andre, MD, professor of medical oncology, University Pierre et Marie Curie (UMPC), and Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique Hôpitaux de Paris, discusses the future of immunotherapy for patients with metastatic colorectal cancer.